Moderna Announces Coronavirus Vaccine Efficacy Of Nearly 95% In Preliminary Clinical Trial Results; Media Outlets Report On Other Vaccine Research, Issues

Washington Post: Moderna’s coronavirus vaccine found to be nearly 95 percent effective in a preliminary analysis
“Biotechnology firm Moderna announced Monday that a preliminary analysis shows its experimental coronavirus vaccine is nearly 95 percent effective at preventing illness, including severe cases — a striking initial result that leaves the United States with the prospect that two coronavirus vaccines could be available on a limited basis by the end of the year. The news comes a week after pharmaceutical giant Pfizer and its German partner BioNTech lifted the stock market and people’s hopes with the news that their coronavirus vaccine was more than 90 percent effective. … Moderna’s vaccine, co-developed with [Anthony] Fauci’s institute, is being tested in 30,000 people…” (Johnson, 11/16).

Additional coverage of Moderna’s announcement is available from AP, Bloomberg, CNBC, CNN, Reuters, and Wall Street Journal.

The Atlantic: Listen: A 90 Percent Effective Vaccine (Hamblin, 11/13).

CIDRAP News: Feds update vaccine arrival amid record U.S. COVID-19 rise (Schnirring, 11/13).

Financial Times: J&J to launch U.K. trial of its Covid-19 vaccine (Mancini, 11/15).

Forbes: Pfizer Has A Head Start, But The Covid-19 Vaccine Market Is Still Up For Grabs (Jennings, 11/13).

NBC News: The promise of coronavirus vaccine at a factory in India — and the looming fight over it (Engel et al., 11/15).

New York Times: How Pfizer Plans to Distribute Its Vaccine (It’s Complicated) (Robbins/Gelles, 11/12).

NPR: Who Gets The Vaccine First? And How Will They Get It? (Sophia et al., 11/16).

The Observer/Guardian: Speedy work on Covid gives the vaccine industry a shot in the arm (Kollewe, 11/14).

STAT: J&J supply chain exec: ‘I lose sleep’ over sending Covid-19 vaccine to lower-income countries (Silverman, 11/16).

The Telegraph: Oxford seeks to keep pace in hunt for game-changing vaccine (Boland, 11/16).

The Telegraph: How a deep-frozen vaccine reached 400,000 people, helped stop Ebola and holds hope for coronavirus (Rigby, 11/15).

TIME: Why You May Not Be Able to Get Pfizer’s Frontrunner COVID-19 Vaccine (Ducharme, 11/13).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.